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INTRODUCTION 
Dementia is a syndrome due to disease of the brain – 
usually of a chronic or progressive nature – in which there 
is disturbance of multiple higher cortical functions, 
including memory, thinking, orientation comprehension, 
calculation, learning capacity, language, and judgement. 
Consciousness is not clouded. The impairments of 
cognitive function are commonly accompanied, and 
occasionally preceded, by deterioration in emotional 
control, social behaviour, or motivation. This syndrome 
occurs in a large number of conditions primarily or 
secondarily affecting the brain.1 
Alzheimer’s disease is the most common form 
of dementia and possibly contributes to 60–70% of cases. 
Other major contributors include vascular dementia, 
dementia with Lewy bodies, and a group of diseases that 
contribute to frontotemporal dementia. The boundaries 
between subtypes are indistinct and mixed forms often co-
exist.2  
Epidemiology & Impact of dementia: 
Although dementia is not a normal part of ageing, it 
mainly affects older people. Only 2% of cases start before 
the age of 65 years. After that, the prevalence doubles with 
every five year increment in age. It is estimated that by 
2050 the world population over the age of 60 will be 2 
billion, and a clearly negative effect of rapid ageing of the 
population is the increase in the number of people with 
dementia. 3,4     
       In 2010, it was estimated that 35.6 million worldwide 
and 3.7 million Indians (2.1 million women and 1.5 
million men) are affected with dementia and are expected 
to double by 2030 and three-fold by 2050.The total 
number of new cases of dementia each year worldwide is 
nearly 7.7 million, implying one new case every four 
seconds.3,4,5 
In India the number of people with Alzheimer’s 
disease and other dementias is increasing every year 
because of the steady growth in the older population and 
stable increment in life expectancy. Prevalence of 
dementia using survey diagnosis or clinical diagnosis of 
DSM-IV or ICD 10 reported from Indian studies range 
from 0.6 % to 3.5% in rural areas and 0.9% to 4.8 % in 
urban areas.4 Compared to 2006, Delhi, Bihar and 
Jharkhand are expected to experience about 200% & other 
states about 100% increment in total number of dementia 
cases over the 26 year period.4 
Dementia is often associated with physical, 
mental and financial burden on patients, their families, and 
society. For patients, it leads to increased dependency and 
complicates the other co-morbid conditions. For families, 
it leads to anxiety, depression, and increased time spent 
caring for a loved one.6 
Evidence suggests that elderly people with 
dementia in developing countries do not often utilise 
health care services, and when they do, the health care 
system is often ill prepared to provide quality services for 
dementia. Around 10-37% of the elderly population with 
dementia in developing countries are classified as having 
potentially vulnerable living circumstances with requiring 
long-term and specialised care.7 
In 2010, the total estimated costs of dementia 
were US$ 604 billion worldwide and about Rs. 14,700 
crore in India.4,5 It includes health care and related costs as 
well as lost wages for patients and family caregivers.6 
It is predicted that the economic burden of 
dementia in the Asian region will increase from 58% in 
2005 to 68% in 2030, while other conditions (stroke, 
musculoskeletal disorders, cardiovascular disease and all 
forms of cancer) will fall from 31% to 19% in 2030.8 
Morbidity & Mortality of dementia: 
Dementia is also, one of the major causes of disability in 
later life. It accounts for 11.9% of the years lived with 
disability due to a non-communicable disease in people 
aged 60 years and older. The WHO Report estimated that 
dementia is the second highest source of disease burden 
after tropical disease.5 
The global age standardised death rate for AD and 
other dementias is 6.7 per 100,000 for males and 7.7 per 
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100,000 females. For India and WHO SEARO D-sub 
region, the dementia mortality rate is 13.5 per 100,000 
males and 11.1 per 100,000 females. Compared to other 
chronic medical conditions (heart diseases, cancer and 
stroke), AD is the fourth leading cause of death in the Asia 
Pacific region.4,5 
Diagnosis of dementia: 
Dementia is caused by various diseases and 
conditions that result in damaged brain cells. To diagnose 
someone with dementia, the following criteria is widely 
used: 9 
A) A decline in memory and in at least one of the 
following cognitive abilities: 
 Ability to generate coherent speech or understand 
spoken or written language;  
 Ability to recognize or identify objects, assuming intact 
sensory function;  
 Ability to execute motor activities, assuming intact 
motor abilities, sensory function and comprehension of 
the required task; and  
 Ability to think abstractly, make sound judgments and 
plan and carry out complex tasks.  
B) The decline in cognitive abilities must be severe enough 
to interfere with daily life. 
Two main types of criteria are used for diagnosis of 
dementia in India: 
1) The DSM-IV criteria (The Diagnostic and Statistical 
Manual for Mental Disorders, Fourth Edition), 
developed by American Psychiatry Association.10 
2) The 10/66 dementia diagnosis: This criterion relies on 
an algorithm which was validated in an extensive pilot 
study conducted in India and other countries. It has an 
overall sensitivity of 94% and a specificity of 97% for 
those with higher and 94% for those with lower levels 
of education.7,11 
Course and outcome of dementia: 
The symptoms and problems linked to dementia can be 
best understood in three stages:-2 
1) Early stage (developed in 1-2 years): The early stage 
of dementia is often overlooked because the onset of 
dementia is gradual. The person may have problems in 
talking properly (language problems) or have 
significant memory loss – particularly for things that 
have just happened or not know the time of day or the 
day of the week. 
2) Middle stage (developed in second to fifth year): As 
the disease progresses, limitations become clearer and 
more restricting. The person with dementia has 
difficulty with day-to-day living and may become 
very forgetful – especially of recent events and 
people’s names or can no longer manage to live alone 
without problems or unable to cook, clean or shop. 
3) Late stage (developed in fifth year or after): This stage 
is one of near total dependence and inactivity. 
Memory disturbances are serious and the physical side 
of the disease becomes more obvious. The person may 
have difficulty eating, be incapable of communicating, 
not recognize relatives, friends and familiar objects, 
display inappropriate behavior in public and may 
become confined to a wheel chair or bed. 
There is impairment in short term and long term memory, 
particularly the inability to learn and recall new 
information. Problems with abstract thinking and 
judgement occur, as well as the loss of higher cortical 
functions causing language difficulties, motor 
impairments, problems with recognition, and personality 
changes. Eventually, neurological destruction affects all 
bodily systems, and people generally die of illnesses of 
debility such as pneumonia (Lezak et al., 2004:207).12 
In low and middle income countries, diagnosis is often 
much delayed, and survival is less than 5-7 years.13 
Aetiology & Risk factors: 
 Advanced age remains the main risk factor for 
most forms of dementia, with prevalence roughly doubling 
every five years over the age of 65 in India.2 
Onset before 65 year of age is rare and, in the case 
of Alzheimer’s disease (AD), often suggests a genetic 
cause. Single gene mutations of either β-amyloid precursor 
protein or presenilin-1 or presenilin-2, account for most of 
the cases of early onset AD.14,15 
For late-onset of AD, both environmental 
(lifestyle) and genetic factors are important. A common 
genetic polymorphism, the apo-lipoprotein E (apoE) gene 
e4 allele, greatly increases the risk of dementia. Up to 25% 
of the population has one or two copies of this allele.14,15 
The evidence strongly establishes a causal role of 
cardiovascular risk factors and cardiovascular disease in 
the aetiology of dementia and AD. Those with high 
cardiovascular risk scores (incorporating hypertension, 
diabetes, hypercholesterolemia and smoking) have an 
increased risk for dementia.16 Recent studies support the 
associations between metabolic syndrome and cognitive 
decline, and also between insulin resistance and impaired 
executive function.17 Diabetes, hypertension and 
hypercholesterolemia are also associated with the onset of 
AD. Depression, head injury, limited education etc. is 
found to be associated with AD in a few studies, but strong 
evidences are lacking.18,19 
Neuropathology of dementia: 
Dementia is not a disease but is a syndrome of 
progressive cognitive decline caused by numerous 
different pathologies. In early stages cognitive 
symptomatology differs with different aetiologies, 
however as neurodegenerative pathology progresses, then 
the marked destruction of brain tissue produces similar 
symptoms whatever be the cause.12 
Macroscopically, brain is atrophic resulting in 
secondary enlargement of ventricles. Atrophy occurs in 
specific areas of the brain, including the frontal, temporal 
and parietal cortex and the hippocampus. Microscopically, 
Alzheimer Disease is characterized by degeneration of 
neurons especially synapses and dendrites, along with the 
presence of β-amyloid (βA) plaques, neurofibrillary 
tangles (NFTs) and granulovascular degeneration 
throughout the cortex and sub-cortical grey matter. More 
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than 50% of AD patients show white matter changes called 
as selective incomplete white matter infarctions.20 
β-amyloid perturbs cellular properties by multiple 
mechanisms, including induction of oxidant stress by 
binding and entrapping the metals in the plaque, metals 
catalyze the conversion of H2O2 to hydroxyl radicals (OH) 
in excess, challenging cellular antioxidants defenses and 
redirecting protein synthesis. Oxidant-related activation of 
the transcription factor-kB (NF-kB), for example, induces 
expression of cytokines and cell adherence molecules, 
thereby modulating cell-cell interactions.20  
The β-amyloid can bind to specific receptor, such 
as RAGE (receptor for advanced glycation end products) 
or type-2-scavenger receptor, may induce free radical 
production by stimulating the activity of the reduced form 
of nicotinamide adenine dinucleotide oxidases. The 
accumulation of excitatory amino acids such as L-
glutamate can induce nerve cell death by over activation of 
specific glutamate receptors or by the induction of 
oxidative events. The latter are initiated by the competition 
of glutamate for the neuronal cysteine-antiporter system 
that in a first step leads to a depletion of intracellular 
glutathione and in a second step to an accumulation of 
H2O2. The consequences are the peroxidation of membrane 
lipids by oxidative chain reaction and the lysis of the 
cells.20,21 
 There occurs a depletion of the neurotransmitter 
acetylcholine and the enzyme which produces it- choline 
acetyltransferase, along with other neurotransmitters and 
neurochemicals (World Health Organisation, 1992, cited in 
Henderson & Jorm, 1998). These changes result in 
diminished cognitive function that worsens as the disease 
progresses.
 
Major types of dementia and their characteristics:
9 
Types of Dementia Characteristics 
 
Alzheimer’s disease 
 Most common type of dementia; accounts for 60 to 80 percent of cases. 
 Difficulty remembering names and recent events is often an early clinical symptom; apathy 
and depression are also often early symptoms. 
 Later symptoms include impaired judgment, disorientation, confusion, behaviour changes, and 
trouble in speaking, swallowing and walking. 
 Hallmark abnormalities are deposits of the protein fragment beta-amyloid (plaques) and 
twisted strands of the protein tau (tangles). 
Vascular dementia (also 
known as multi-infarct 
dementia or vascular 
cognitive impairment) 
Considered the second most common type of dementia. 
 Impairment is caused by decreased blood flow to parts of the brain, often due to a series of 
small strokes that block arteries. 
 Symptoms often overlap with those of Alzheimer’s, although memory may not be as seriously 
affected. 
Mixed type 
 
Characterized by the presence of the hallmark abnormalities of Alzheimer’s and another type 
of dementia, most commonly vascular dementia, but also other types, such as dementia with 
Lewy bodies. 
Dementia with Lewy 
bodies 
Pattern of decline may be similar to Alzheimer’s, including problems with memory and 
judgment and behaviour changes. 
 Alertness and severity of cognitive symptoms may fluctuate daily. 
 Visual hallucinations, muscle rigidity and tremors are common. 
 Hallmarks include Lewy bodies (abnormal deposits of the protein alpha-synuclein) that form 
inside nerve cells in the brain. 
Parkinson’s disease 
 
Many people who have Parkinson’s disease develop dementia in the later stages of the disease. 
 The hallmark abnormality is Lewy bodies (abnormal deposits of the protein alpha-synuclein) 
that form inside nerve cells in the brain. 
Fronto temporal 
dementia 
Involves damage to brain cells, especially in the front and side regions of the brain. 
 Typical symptoms include changes in personality and behaviour and difficulty with language. 
 No distinguishing microscopic abnormality is linked to all cases. 
 Pick’s disease, characterized by Pick’s bodies, is one type of front temporal dementia. 
 
Creutzfeldt-Jakob 
disease 
 
 Rapidly fatal disorder that impairs memory and coordination and causes behaviour changes. 
 Variant Creutzfeldt-Jakob disease is believed to be caused by consumption of products from 
cattle affected by mad cow disease. Caused by the misfolding of prion protein throughout the 
brain. 
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Management of dementia: The standard treatment goals 
of dementia management include: 2 
1) Early diagnosis.  
2) Optimization of physical health, cognition, activity 
and well being.  
3) Detection and treatment of Behavioural and 
Psychological Symptoms of Dementia.  
4) Educating care takers and providing long term support 
to them. 
5) Carer interventions such as Psycho-educational 
interventions, Psychological therapies, e.g. cognitive 
behavioural therapy (CBT), counselling and Respite 
care. 
Treatment for memory disorders:-
22,23 
The memory can be improved by non 
pharmacological measures such as simple lifestyle changes 
like incorporating memory exercises, healthy eating 
(Omega-3 fatty acids and vitamin rich diets, fish, fruits, 
vegetables etc.), physical fitness and stress reduction into 
daily lives.  
   Pharmacological treatment includes variety of 
agents, such as Acetylcholinestrase inhibitors (e.g. 
Galantamine, Donepezil), GABA antagonists (e.g. 
Suritozole- α5 partial inverse agonist), Glutamate 
activators (e.g. Ampakines, Racetams etc), Serotonergics, 
Anti-depressants, mood stabilizers and antioxidants. 
List of drugs used in treatment of dementia 
 Precursors to acetylcholine (Ach) - they increase 
amount of Ach, e.g., choline and Lecithin  
 Acetylcholinesterase  inhibitors- prevent the 
breakdown of Ach. e.g, tacrine, galantamine, 
donepezil, rivastigmine and velnacrine 
 Cholinergic agonists e.g., bethnicol- it is a muscarinic 
agonists 
 Neuroprotective drugs like acetyl-carnitine- it 
promotes Ach synthesis 
 Anaesthetics e.g. procaine Hcl- it is a mild CNS 
stimulant with weak MaO inhibitory action. 
 Chelators e.g. EDTA, Desferioxamine- they help in 
removal of toxins. 
 Nerve growth factors – attenuate the degeneration of 
remaining cholinergic neurons. 
 Neuropeptides e.g. ACTH, Somatostatin – they may 
enhance the activity of endogenous neurotransmitters. 
 Calcium channel blockers e.g. Vasopressin, 
Nimodipine – they inhibit calcium influx associated 
with cellular damage. 
 Cognition enhancers/Nootropic agents e.g. 
Piracetam,cyclothiazide, and CX-516 (Ampalex),– 
they are positive AMPA receptor modulators known 
as ampakines. They increase AMPA-mediated 
synaptic responses and enhance long-term potentiation 
as well as upregulating the production of nerve growth 
factors such as brain-derived neurotrophic factor 
(BDNF). 
 Psychostimulants e.g. Methyl phenidate, Pemoline, 
Selegilline – they stimulate CNS & irreversibly inhibit 
MAO. 
 Vasodilators e.g.  Cyclandelate, Isoxsuprine, 
Papaverine – enhance blood flow to the brain.   
Although a few specific drugs such as 
Acetylcholinesterase inhibitors show modest clinical 
efficacy in AD patients, they do not affect the underlying 
pathology and this, coupled with strong side effects, results 
in questionable usefulness of these drugs. There is 
evidence that these medications can slow the progression 
of symptoms initially, but don’t change the overall 
outcome or prognosis (Lopez, et al., 2002). So, the search 
for effective therapeutic strategies continues. 
Newer approaches towards treatment of dementia: 
The search for new effective therapies is the need 
of the hour because of the following reasons: 1) To delay 
the onset of dementia & to effectively control the disease 
progression. 2) To control all the pathological aspect of 
dementia. 3) To reduce the cost burden of dementia 
management. 4) To improve the safety profile of the drugs. 
Scarpini et al. (2003) identify three promising areas of 
research:24 
a) Reduction of risk factors- such as oxidative stress, 
cardiovascular risk factors and inflammation. 
b) Neurogenesis promotion- via stem cell transplantation 
and nerve growth factors. 
c) Prevention and removal of amyloid plaque via vaccine 
and chelation agents. 
Two important strategies for reduction of the risk 
factors are:  
1) Nutritional approaches (e.g. calorie restriction, 
consumption of fish, monounsaturated oils and 
antioxidants, especially vitamins C and E) 
2) Use of herbal medicines.  
Plant products used in the treatment of memory 
disorder:
25 
Plant medicines that reputedly act to improve 
function of the central nervous system are a promising area 
for research. They are most likely to offer benefits in the 
above mentioned ‘reduction of risk factors’ category of 
therapy, because many phytochemicals from plants are 
now known to be powerful antioxidants, and many also 
possess a cholinergic modulation effect and  anti-
inflammatory actions. This is a significant effect because, 
as highlighted earlier, cholinergic deficits are a feature of 
dementia. Some of the important herbs, which have shown 
positive results in preclinical and clinical trials, are Ginkgo 
biloba, Bocopa monniera, Withania somnifera, Curcuma 
longa, Acorus calmus etc. 
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